form_8-k.htm
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington,
DC 20549
_______________
Form 8-K
_______________
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of
report (date of earliest event reported):
May
5, 2008
_______________
SCOLR
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
_______________
|
|
|
|
|
|
|
Delaware
|
|
001-31982
|
|
91-1689591
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File No.)
|
|
(I.R.S.
Employer Identification No.)
|
3625
132nd Avenue SE, Suite 400
Bellevue,
WA 98006
(Address
of principal executive offices)
(425) 373-0171
(Registrant’s
telephone number, including area code)
_______________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item 7.01
Regulation FD Disclosure.
Representatives
of SCOLR Pharma, Inc. will use the materials attached hereto as Exhibit 99.1 in
investor presentations from time to time. We have also posted the presentation
materials on our company website at www.scolr.com.
Please
refer to page 2 of Exhibit 99.1 for a discussion of certain forward-looking
statements included in the presentation materials. These forward-looking
statements involve risks and uncertainties, including activities, events or
developments that we expect, believe or anticipate will or may occur in the
future. A number of factors could cause actual results to differ from those
indicated in the forward-looking statements, including our ability to
successfully develop new formulations and complete research and development,
including pre-clinical and clinical studies, our ability to raise additional
funds, the continuation of arrangements with our product development partners
and customers, competition, government regulation and approvals, and general
economic conditions. In order to obtain regulatory approvals for the commercial
sale of potential products utilizing our CDT platform, we may be required to
complete clinical trials in humans to demonstrate the safety and efficacy, or in
certain cases, the bioequivalence, of the products. However, we may not be able
to commence or complete these clinical trials in any specified time period, or
at all, either because the appropriate regulatory agency objects or for other
reasons. We plan to continue the costly process of simultaneously conducting
clinical trials and preclinical research for multiple product candidates.
Additional assumptions, risks and uncertainties are described in detail in our
registration statements, reports and other filings with the Securities and
Exchange Commission. Such filings are available on our website or at
www.sec.gov.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
|
Exhibit No.
|
Description
|
|
99.1
|
Presentation
materials for the investor presentation by SCOLR Pharma,
Inc.
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
SCOLR
PHARMA, INC.
|
|
Dated: May
5, 2008
|
By:
|
/s/
Alan M. Mitchel
|
|
|
|
Alan
M. Mitchel
Senior
Vice President Business and Legal Affairs
and
Chief Legal Officer
|